menu
    • menu
    [{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bryden Stokes Limited","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Bryden Stokes Limited","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Bryden Stokes Limited"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Applied Research Centre at Langara College"},{"orgOrder":0,"company":"Avicanna","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ University Health Network","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ University Health Network"},{"orgOrder":0,"company":"Raphael Pharma","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Raphael Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharma \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Raphael Pharma \/ Citruslabs"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon State University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oregon State University \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"MediPharm Labs \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Undisclosed"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emerald Health Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Emerald Health Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"||CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"MediPharm Labs \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol

    Menu

    2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Raphael Pharma

                            Country arrow
                            Organic Process R&D
                            Not Confirmed

                            Raphael Pharma

                            Country arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Citruslabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

                            Details : Cannabigerol is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Citruslabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $0.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Avicanna Announces Closing of Non-Brokered Private Placement

                            Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...

                            Product Name : RHO Phyto

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $0.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $1.4 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units

                            Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...

                            Product Name : RHO Phyto

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            August 02, 2023

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $1.4 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Applied Research Centre at Langara College

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avicanna and Langara College Announce Cannabinoid-based Translational Research Collaboration and NSERC Grant

                            Details : The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios...

                            Product Name : RHO Phyto

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 13, 2023

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Applied Research Centre at Langara College

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $1.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

                            Details : Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, mark...

                            Product Name : RHO Phyto

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 13, 2022

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : $1.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MediPharm Labs

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabigerol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

                            Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.

                            Product Name : CBG/CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Cannabigerol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MediPharm Labs

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabinoid,Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

                            Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Cannabinoid,Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Oregon State University

                            Country arrow
                            Organic Process R&D
                            Not Confirmed

                            Oregon State University

                            Country arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oregon State Research Shows Hemp Compounds Prevent Coronavirus From Entering Human Cells

                            Details : According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 10, 2022

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Bryden Stokes Limited

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbado...

                            Details : Avicanna has entered into a distribution partnership with Bryden Stokes, an established health and pharmaceutical product distributor in the Caribbean region to distribute its medical formulary RHO Phyto line of products.

                            Product Name : RHO Phyto

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            November 25, 2021

                            Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Bryden Stokes Limited

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            180 Life Sciences

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            180 Life Sciences

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflamm...

                            Details : HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precurso...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : Cannabigerol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth